Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib as conversion therapy in potentially resectable HCC
NCT04241523Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04241523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241523.